Weight loss drugs may become harder to get. What does that mean for patients?

Dr. Jodi Dushay, an assistant professor at Harvard Medical School specializing in weight management, joins reporter Daniel Gilbert from The Washington Post to discuss critical issues surrounding weight loss drugs. They explore FDA shortages that have led to a boom in compounded medications, the growing challenges of accessibility, and the controversial costs associated with popular treatments like Ozempic. The duo also tackles the implications of insurance policies and societal perceptions of weight, offering insights into the evolving landscape of weight loss treatments.